Processing

Please wait...

Settings

Settings

Goto Application

1. WO2007147373 - PHARMACEUTICAL COMPOSITION FOR INJECTIONAL, PARTICULARLY TARGETED LOCAL ADMINISTRATION

Publication Number WO/2007/147373
Publication Date 27.12.2007
International Application No. PCT/CZ2007/000060
International Filing Date 20.06.2007
IPC
A61K 33/24 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
24Heavy metals; Compounds thereof
C07F 15/00 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
FACYCLIC, CARBOCYCLIC, OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
15Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
CPC
A61K 31/282
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
28Compounds containing heavy metals
282Platinum compounds
A61K 33/24
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
24Heavy metals; Compounds thereof
A61K 47/26
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/38
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
38Cellulose; Derivatives thereof
A61K 9/0019
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • PLIVA-LACHEMA A.S. [CZ]/[CZ] (AllExceptUS)
  • FRANC, Ales [CZ]/[CZ] (UsOnly)
  • SOVA, Petr [CZ]/[CZ] (UsOnly)
Inventors
  • FRANC, Ales
  • SOVA, Petr
Agents
  • KUBÁT, Jan
Priority Data
PV 2006-40120.06.2006CZ
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) PHARMACEUTICAL COMPOSITION FOR INJECTIONAL, PARTICULARLY TARGETED LOCAL ADMINISTRATION
(FR) COMPOSITION PHARMACEUTIQUE POUR ADMINISTRATION LOCALE PAR INJECTION PARTICULIÈREMENT CIBLÉE
Abstract
(EN)
The invention relates to a pharmaceutical composition for injectional, in particular targeted local administration, characterized in that it comprises a sterile suspension of platinum complex of general formula (I), wherein A and A' independently of one another are an NH3 group or an amino or diamino group containing 1 to 18 carbon atoms, B and B' independently of one another are a halogen atom or a hydroxy group or are an -0-C(O)-R or an -0-C(O)-R' group wherein R and R' independently of one another are hydrogen atom, an alkyl, alkenyl, aryl, aralkyl, alkylamino or alkoxy group which groups contain 1 to 10 carbon atoms, or functional derivatives of these groups, X and X' independently of one another are a halogen atom or a monocarboxylate group containing 1 to 20 carbon atoms, or X and X' together form a dicarboxylate group containing 2 to 20 carbon atoms, in a pharmaceutically acceptable hydrophilic or hydrophobic injection liquid phase, 100 % of particles of the platinum complex of general formula I being of size smaller than 250 &mgr;m.
(FR)
La présente invention concerne une composition pharmaceutique pour administration locale par injection particulièrement ciblée. Cette composition est caractérisée en ce qu'elle comprend une suspension stérile de complexe de platine de formule générale (I), dans laquelle A et A' représentent indépendamment un groupe NH3 ou un groupe amino ou diamino contenant de 1 à 18 atomes de carbone, B et B' représentent indépendamment un atome d'halogène, un groupe hydroxy ou un groupe -O-C(O)-R ou -O-C(O)-R', où R et R' représentent indépendamment un atome d'hydrogène, un groupe alkyle, alcényle, aryle, aralkyle, alkylamino ou alkoxy contenant de 1 à 10 atomes de carbones, ou des dérivés fonctionnels de ces groupes, X et X' représentent indépendamment un atome d'halogène ou un groupe monocarboxylate contenant de 1 à 20 atomes de carbone ou X et X' forment conjointement un groupe dicarboxylate contenant de 2 à 20 atomes de carbone, dans une phase liquide d'injection hydrophile ou hydrophobe pharmaceutiquement acceptable, 100% des particules du complexe de platine de formule générale (I) présentant une taille inférieure à 250 &mgr;m.
Latest bibliographic data on file with the International Bureau